Structure of LY294002
CAS No.: 154447-36-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
LY294002 is a PI3K inhibitor with IC50 values of 0.5 μM for PI3Kα, 0.57 μM for PI3Kδ, and 0.97 μM for PI3Kβ. LY294002 has anti-tumor effects and is used to study the PI3K/AKT signaling pathway and related cancer treatments.
Synonyms: SF 1101; NSC 697286
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Keratin 19 interacts with GSK3β to regulate its nuclear accumulation and degradation of cyclin D3
Sharma, Pooja ; Tiufekchiev, Sarah ; Lising, Victoria ; Chung, Seung Woo ; Suk, Jung Soo ; Chung, Byung Min
Abstract: Cyclin D3 regulates the G1/S transition and is frequently overexpressed in several cancer types including breast cancer, where it promotes tumor progression. Here we show that a cytoskeletal protein keratin 19 (K19) phys. interacts with a serine/threonine kinase GSK3β and prevents GSK3β -dependent degradation of cyclin D3. The absence of K19 allowed active GSK3β to accumulate in the nucleus and degrade cyclin D3. Specifically, the head (H) domain of K19 was required to sustain inhibitory phosphorylation of GSK3βSer9, prevent nuclear accumulation of GSK3β,and maintain cyclin D3 levels and cell proliferation. K19 was found to interact with GSK3β and K19-GSK3β interaction was mapped out to require Ser10 and Ser35 residues on the H domain of K19. Unlike wildtype K19, S10A and S35A mutants failed to maintain total and nuclear cyclin D3 levels and induce cell proliferation. Finally, we show that the K19-GSK3β-cyclin D3 pathway affected sensitivity of cells toward inhibitors to cyclin-dependent kinase 4 and 6 (CDK4/6). Overall, these findings establish a role for K19 in the regulation of GSK3β-cyclin D3 pathway and demonstrate a potential strategy for overcoming resistance to CDK4/6 inhibitors.
Show More >
Regulation of Cell Cycle Progression by Keratin 19 in Breast Cancer Cells
Sharma, Pooja ;
Abstract: Keratins are widely used as diagnostic markers to detect tumors in both primary and distal sites and to determine tumors’ tissue of origin in order to aid in treatment strategies. In this regard, K19 has been particularly useful because it is among the most sensitive diagnostic markers across a broad range of cancer types. K19 has also been shown to be one of the most reliable prognostic markers for multiple tumor types, including breast cancer where higher expression of K19 is correlated with worse patient survival. Despite the clinical data showing positive correlation between increased K19 expression and poor survival rates among patients of breast cancer types, the role of K19 in breast cancer remains unclear. To understand the role of K19 in breast cancer, we generated KRT19 knockout (KO) cell lines using MCF7 and MDA-MB-231 breast cancer cell lines. Using this system, we found that KRT19 KO cells exhibit reduced proliferation compared to parental control cells and uncovered a cell cycle promoting role of K19. We identified that K19 promotes proliferation of cancer cells by stabilizing a cell cycle regulator cyclin D3. However, how a cytoskeletal protein regulates levels of cyclin D3 remained unknown. It has been known that GSK3β play a crucial role in degrading cyclin D3 for proteasomal degradation. In our study in MCF7 cells, we identified GSK3β as a keratin-interacting protein and found that K19 suppressed GSK3β activity by inhibiting its nuclear accumulation. GSK3β-binding by K19 required serine 10 and 35 residue as K19 S10A or S35A mutation failed to protect cyclin D3 from protein degradation. Our results reveal a novel regulatory role of K19 on GSK3β localization and activity as a mechanism of how a cytoskeletal protein stabilizes a cell cycle regulator and promotes proper cell proliferation. In addition, we found that K19 expressing cells are more sensitive to cyclin dependent kinase (CDK) 4/6 inhibitors as compare to KRT19 KO cells. The sensitivity of KRT19 KO cells to CDK4/6 inhibitor was increased when cotreated with a GSK3β inhibitor, demonstrating that the K19-GSK3β axis plays a critical role in drug resistance. Given that K19 expression levels are frequently elevated in various cancers, K19 can be used to predict the efficacy of CDK4/6 inhibitors and patients may be cotreated with a GSK3β inhibitor to avoid drug resistance.
Show More >
CAS No. : | 154447-36-6 |
Formula : | C19H17NO3 |
M.W : | 307.34 |
SMILES Code : | O=C1C=C(N2CCOCC2)OC3=C1C=CC=C3C4=CC=CC=C4 |
Synonyms : |
SF 1101; NSC 697286
|
MDL No. : | MFCD00270881 |
InChI Key : | CZQHHVNHHHRRDU-UHFFFAOYSA-N |
Pubchem ID : | 3973 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H332-H335 |
Precautionary Statements: | P261-P280-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
ADSCs | 50 µM | 24 h | To investigate the role of PI3K signaling on rGO/PCL induced neurotrophic phenotype changes and myelin protein secretion. | PMC9640298 |
H9C2 cells | 25 μM | 30 min | To explore the mechanisms of NGR1's protective effect on H9C2 cells. | PMC9287735 |
chondrocytes | 20 μM | 3 days | The study aims to investigate the effects of blood on chondrocyte viability and apoptosis. | PMC11076293 |
MLE-12 cells | 50 μg/mL | 24 h | LY294002 was used as a positive control to inhibit up-regulated expression of fibrosis-related genes. | PMC11515248 |
BMSCs | 20 µM | 0, 15, 30, 60, 120 min | LY294002 significantly inhibited the higher expression of osteogenic genes induced by Ginsenoside Rb1. | PMC8841501 |
CTLL-2 cells | 50 μM | 48 h | The purpose was to analyze the effect of LY294002 on the CTLL-2 cells in the presence of IL-7. | PMC10542607 |
Astrocytes | 40 μM | immediately post-OGD/R | To inhibit PI3K signaling pathway and evaluate its effects on glycophagy. | PMC11215420 |
hWJ-MSCs | 40 µM | 2 h | Estimate the effects of the AKT inhibitor on the proliferation of FP2-cultured hWJ-MSCs. | PMC11331723 |
RAW 264.7 | 10 µM | 24 h | To evaluate the effect of LY294002 on macrophage polarization. | PMC11162076 |
SKMEL28 melanoma cells | 20 µM | 2 h | The study involved the inhibition of AKT signaling to determine the effects on oxidative DNA damage repair; results showed reduced expression of OGG. | PMC11002308 |
various TNBC cell lines | 2 μM | 10 days | to investigate the effect of MAPK4 knockdown on cell growth and sensitivity to PI3K inhibitors | PMC8752662 |
Human fetal RPE cells | 2 μM | 4 days | To investigate the effect of glucose concentration on inflammatory responses, where inflammatory markers were evaluated. | PMC9561713 |
NHA/HRasV12/TRIM24 cells | 0.01 to 100 μM | 24, 48, and 72 h | Cell proliferation was evaluated and the half-maximal inhibitory concentration (IC50) values were determined from fitted concentration-response curves. | PMC11304257 |
RF24 cells | 50 µM | 6 h | The treatment resulted in reduced angiogenesis as inferred from subsequent experiments. | PMC10133315 |
HAEC and HSMEC | 50 nM | 30 min | To evaluate the effect of LY294002 on insulin uptake. | PMC10435471 |
U-251 and Ca9-22 cells | 20 μm | 2 h | To assess the impact of PI-3 kinase inhibition on cell behavior. | PMC9982589 |
hESCs | 10 µM | 24 h | To investigate the role of LY294002 in influencing differentiation to endoderm. | PMC9876972 |
Astrocytes | 10 µM | 1 h | AMPK inhibition reduces collective cell migration and invasion efficiency. | PMC9372137 |
Vascular Smooth Muscle Cells (VSMC) | 50 μM | 30 min | To inhibit the activation of Akt and study the effects on related signaling pathways. | PMC8980891 |
Human embryonic stem cells | 5 μM | 8 days | Induction of neuroectoderm differentiation. | PMC11109972 |
HUVECs | 5 μg/mL | variable (6, 24, 48, and 72 h) | to observe the effects of the PI3K inhibitor as a negative control | PMC9972357 |
Primary chondrocytes | 10 µM | 24 h | LY294002 administration significantly reduced SNP-induced apoptosis activities and alleviated aberrant force-induced chondrocyte degeneration. | PMC9279410 |
RAW264.7 cells | 25 µM | 1 h | Inhibit PI3K signaling pathway and reduce M1 macrophage polarization | PMC11295337 |
BMDMs | 25 µM | 1 h | Inhibit PI3K signaling pathway and reduce M1 macrophage polarization | PMC11295337 |
neonatal rat cardiomyocytes (NRCMs) | 10 μM | 2 h | Inhibited PI3K α/AKT signaling, reversed FGF7-mediated promotion of Nrf2 nuclear translocation, and increased ROS levels and apoptotic cells | PMC9482143 |
human dental pulp stem cells | 10 µM | 7 days | LY294002 attenuated the responsiveness of 10−6 M insulin to IIS/PI3K/AKT/mTOR pathway axis, suppressing the promoting effect of insulin on cell proliferation, osteogenic differentiation and bone formation. | PMC11287875 |
PC-9R cells | 25 μM | Inhibited the PI3K/AKT pathway and restored sensitivity to gefitinib in PC-9R cells | PMC8990424 | |
BMDMs | 0.5 μM | 2 h | Inhibited PI3K/Akt/Nrf2 signaling pathway and increased NLRP3/Caspase-1/GSDMD protein expression | PMC10060206 |
A549 cells | 10μM | 1 h | Inhibited PI3K/AKT signaling pathway, alleviated TGF-β1-induced epithelial-mesenchymal transition (EMT) | PMC8959854 |
Huh7-SR cells | 5 µM | 1 h | Inhibited PI3K/Akt pathway, reduced Nrf2 nuclear translocation, and increased ferroptosis level | PMC8980859 |
HepG2-SR cells | 5 µM | 1 h | Inhibited PI3K/Akt pathway, reduced Nrf2 nuclear translocation, and increased ferroptosis level | PMC8980859 |
Mouse primary hepatocytes | 10 μM | 1.5 h | To evaluate the relationship between PI3K/AKT pathway and ferroptosis, LY294002 pretreatment exacerbated ferroptosis | PMC11495534 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | Experimental autoimmune hepatitis model | Intraperitoneal injection | 30 mg/kg | Pretreatment 30 minutes before | Inhibit PI3K signaling pathway and reduce FGF4's regulatory effect on M1 macrophages | PMC11295337 |
C57BL/6 mice | Myocardial infarction model (LAD ligation) | Intraperitoneal injection | 2.5 mg/kg | From LAD operation to 7 days post-operation | Inhibited PI3K α/AKT signaling, abolished FGF7-mediated regulation of Nrf2 and HXK2, and exacerbated myocardial oxidative stress and apoptosis | PMC9482143 |
BALB/c nude mice | PC-9R cell xenograft model | Intraperitoneal injection | 2.5 mg/kg | Every three days for 12 days | LY294002 significantly reduced tumor volume and enhanced the anti-tumor effect of gefitinib | PMC8990424 |
C57BL/6 mice | Acute lung injury model | Injection | 20 mg/kg | 24 hours | Inhibited PI3K/Akt/Nrf2 signaling pathway and increased NLRP3/Caspase-1/GSDMD protein expression | PMC10060206 |
Mice | Bleomycin-induced pulmonary fibrosis model | Intraperitoneal injection | 25 mg/kg | Every other day for 21 days | Inhibited PI3K/AKT signaling pathway, alleviated bleomycin-induced pulmonary fibrosis and EMT | PMC8959854 |
NOD mice | Diabetes model | Intraperitoneal injection | 75 mg/kg | Daily for 3 days | Inhibition of PI3K signaling pathway to observe its effect on CD4+ T cell migration | PMC5101163 |
NOD-SCID mice | Subcutaneous tumor model | Intraperitoneal injection | 25 mg/kg | Twice a week for 4 weeks | Inhibited PI3K/Akt pathway, slowed growth of FNDC5-overexpressing HCC cells, and increased ferroptosis level | PMC8980859 |
C57 mice | Liver warm ischemia/reperfusion model | Intraperitoneal injection | 10 mg/kg | Single dose 36 h before liver ischemia followed by 6 h reperfusion | To assess the role of PI3K/AKT pathway in hepatic I/R injury, LY294002 pretreatment abolished the protective effect of rmGas6 and exacerbated ferroptosis | PMC11495534 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02337309 | Neuroblastoma | Phase 1 | Terminated(Low patient accrual... More >>) Less << | - | United States, California ... More >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027-0700 UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 United States, Colorado Children Hospital of Colorado Aurora, Colorado, United States, 80045 United States, Georgia AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Childrens Hospital Boston, Dana-Farber Cancer Institute. Boston, Massachusetts, United States, 02115 United States, Michigan C.S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Texas Cook Children's Healthcare System Fort Worth, Texas, United States, 76104 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.25mL 0.65mL 0.33mL |
16.27mL 3.25mL 1.63mL |
32.54mL 6.51mL 3.25mL |
Tags: LY294002 | LY 294002 | LY-294002 | PI3K | Phosphoinositide 3-kinase | DNA-dependent protein kinase | broad-spectrum | reversibly | Apoptosis | Autophagy | inhibitor | DNA-PK | Casein Kinase | pan-PI3K inhibitor | 154447-36-6
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL